Dr.Zone AI

The Lancet | General Medicine | Dr.Zone AI

The Lancet (General Medicine): [Comment] Will mezigdomide find its place in the T-cell redirecting treatment landscape for relapsed multiple myeloma? The treatment landscape for relapsed or refractory multiple myeloma is rapidly...